Alpha Biopharma Reports the NMPA Acceptance of NDA for Zorifertinib to Treat EGFR-Mutated NSCLC with CNS Metastases
Shots:
- The NMPA has accepted the NDA for Zorifertinib to treat patients with advanced EGFR-mutated NSCLC with CNS metastases
- The P-II/III study (EVEREST) evaluating the efficacy and safety of Zorifertinib in 492 patients at 55 study sites in the Chinese mainland, Taiwan, South Korea & Singapore. The results showed that Zorifertinib effectively reduces the risk of disease progression and patient deaths in the target patient population and also showed significant efficacy in treating metastatic lesions in the CNS
- The safety profile was comparable to other approved EGFR-TKIs. Zorifertinib is a potent, oral, reversible inhibitor of mutated EGFR
Ref: PRNewswire | Image: Alpha Biopharma
Related News:- HUTCHMED and AstraZeneca Report P-II (SAVANNAH) Trial Results of Tagrisso + Savolitinib for EGFR-Mutated NSCLC
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
